Acutaas Chemicals (ACUTAAS)₹3,883−1.13%Pharmaceuticals
In the Sep 2026 quarter (consolidated), Acutaas Chemicals reported sales of ₹437 Cr, up 42.7% from Sep 2025, and net profit of ₹123 Cr, up 71.0% year on year. For the year to Mar 2026, sales were ₹1,340 Cr and net profit ₹356 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 166 | 225 | 177 | 247 | 275 | 308 | 207 | 306 | 393 | 433 | 330 | 437 |
| Expenses | 140 | 182 | 147 | 198 | 206 | 224 | 156 | 211 | 243 | 249 | 217 | 261 |
| Operating Profit | 27.09 | 43.12 | 30.09 | 49.15 | 69.21 | 85.20 | 51.14 | 95.21 | 152 | 184 | 113 | 177 |
| OPM % | 15.9% | 19.0% | 16.9% | 19.9% | 24.9% | 28.0% | 24.9% | 30.9% | 37.9% | 42.0% | 34.0% | 40.0% |
| Other Income | 2.99 | 0.99 | 0.99 | 7.98 | 1.99 | 5.98 | 15.96 | 9.97 | 4.99 | 10.97 | 1.99 | 4.98 |
| Interest | 3.01 | 1.99 | 4.01 | 0.00 | 1.01 | 0.99 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 |
| Depreciation | 3.98 | 4.99 | 5.98 | 6.98 | 5.98 | 6.98 | 7.97 | 7.97 | 9.97 | 9.96 | 9.96 | 12.95 |
| Profit before tax | 23.93 | 36.90 | 19.94 | 49.86 | 62.87 | 82.84 | 57.83 | 95.74 | 145 | 184 | 104 | 167 |
| Tax % | 25.0% | 31.0% | 26.0% | 25.0% | 28.0% | 24.0% | 24.0% | 25.0% | 27.0% | 27.0% | 28.0% | 26.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | 18.01 | 26.01 | 15.01 | 38.03 | 45.05 | 63.04 | 44.02 | 71.97 | 106 | 134 | 75.02 | 123 |
| EPS (Rs) | 2.26 | 3.40 | 1.70 | 4.55 | 5.48 | 7.62 | 5.40 | 8.81 | 13.18 | 16.07 | 9.06 | 15.27 |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 160 | 188 | 239 | 240 | 341 | 520 | 617 | 717 | 1,006 | 1,340 | 1,593 |
| Expenses | 137 | 157 | 196 | 198 | 260 | 414 | 493 | 589 | 774 | 858 | 969 |
| Operating Profit | 23.06 | 31.08 | 42.11 | 42.13 | 80.21 | 105 | 123 | 128 | 233 | 481 | 626 |
| OPM % | 13.9% | 16.0% | 18.0% | 16.9% | 24.0% | 20.0% | 20.0% | 18.0% | 23.0% | 36.0% | 39.3% |
| Other Income | 0.00 | 2.99 | 0.00 | 1.99 | 0.99 | 2.99 | 3.99 | −24.93 | 16.94 | 41.87 | 22.93 |
| Interest | 2.99 | 3.01 | 5.01 | 5.99 | 6.01 | 6.01 | 2.01 | 5.99 | 5.99 | 3.01 | 4.04 |
| Depreciation | 0.99 | 1.99 | 2.99 | 3.99 | 3.98 | 9.96 | 11.97 | 15.95 | 26.91 | 35.86 | 42.84 |
| Profit before tax | 18.94 | 27.95 | 34.91 | 34.90 | 71.80 | 90.80 | 112 | 81.78 | 216 | 482 | 599 |
| Tax % | 35.0% | 35.0% | 34.0% | 21.0% | 25.0% | 21.0% | 26.0% | 41.0% | 26.0% | 26.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | −0.99 | 0.00 | 0.00 | −0.99 | −18.99 | 0.00 | 0.00 | 0.00 |
| Net Profit | 12.01 | 17.99 | 23.01 | 27.03 | 53.98 | 71.98 | 83.02 | 49.01 | 160 | 356 | 438 |
| EPS (Rs) | 1.90 | 2.93 | 3.69 | 4.35 | 8.56 | 9.85 | 11.42 | 5.79 | 19.35 | 43.44 | 53.58 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 15.0% | 13.0% | 26.0% | 8.0% | 6.0% | — |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2.01 | 2.01 | 10.01 | 10.01 | 32.07 | 36.09 | 36.07 | 37.04 | 41.10 | 41.05 |
| Reserves | 37.07 | 56.11 | 72.14 | 101 | 135 | 487 | 559 | 638 | 1,272 | 1,616 |
| Borrowings | 27.09 | 44.09 | 54.16 | 59.18 | 137 | 1.01 | 4.01 | 218 | 13.04 | 36.12 |
| Other Liabilities | 43.11 | 54.15 | 77.24 | 61.29 | 110 | 137 | 170 | 206 | 227 | 296 |
| Total Liabilities | 109 | 155 | 214 | 233 | 414 | 661 | 769 | 1,098 | 1,552 | 1,989 |
| Fixed Assets | 28.02 | 31.98 | 78.99 | 85.03 | 186 | 205 | 259 | 427 | 570 | 745 |
| CWIP | 11.03 | 30.10 | 2.01 | 12.03 | 0.00 | 3.01 | 30.10 | 125 | 130 | 333 |
| Investments | 0.99 | 2.99 | 1.99 | 1.99 | 0.99 | 1.99 | 1.99 | 0.00 | 0.00 | 0.00 |
| Other Assets | 68.24 | 91.29 | 132 | 134 | 226 | 452 | 479 | 545 | 851 | 911 |
| Inventories | 19.95 | 26.94 | 38.96 | 51.87 | 59.86 | 112 | 119 | 157 | 180 | 231 |
| Trade receivables | 36.06 | 50.09 | 76.08 | 56.05 | 121 | 164 | 230 | 206 | 291 | 364 |
| Cash & equivalents | 3.99 | 0.99 | 0.00 | 3.99 | 2.99 | 99.92 | 58.95 | 52.95 | 249 | 225 |
| Total Assets | 109 | 155 | 214 | 233 | 414 | 661 | 769 | 1,098 | 1,552 | 1,989 |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 29.07 | 8.01 | 15.03 | 27.04 | 28.08 | −12.02 | 66.18 | 125 | 118 | 292 |
| Cash from investing activity | −18.94 | −24.92 | −20.92 | −23.91 | −101 | −121 | −32.92 | −364 | −223 | −265 |
| Cash from financing activity | −6.99 | 14.99 | 5.99 | 0.00 | 71.95 | 140 | −12.01 | 239 | 261 | 3.99 |
| Net cash flow | 3.01 | −2.01 | 0.00 | 3.01 | −1.01 | 8.02 | 20.05 | −1.01 | 156 | 30.09 |
| Capex | 17.98 | 24.97 | 20.98 | 21.97 | 107 | 33.99 | 95.92 | 281 | 195 | 327 |
| Free cash flow | 9.98 | −15.97 | −6.99 | 5.99 | −76.81 | −45.89 | −30.92 | −155 | −75.88 | −35.96 |
| CFO / OP % | 153.1% | 53.1% | 68.1% | 85.1% | 52.1% | 10.1% | 73.1% | 116.1% | 71.1% | 84.1% |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 82 | 96 | 115 | 85 | 128 | 114 | 135 | 104 | 104 | 98 |
| Inventory days | 76 | 89 | 95 | 148 | 123 | 150 | 131 | 139 | 119 | 149 |
| Days payable | 148 | 154 | 168 | 146 | 172 | 158 | 157 | 119 | 103 | 99 |
| Cash conversion cycle | 10 | 30 | 42 | 87 | 79 | 106 | 110 | 124 | 120 | 148 |
| Working capital days | 45 | 63 | 27 | 33 | 50 | 140 | 138 | 79 | 122 | 115 |
| ROCE % | — | 38.0% | 34.0% | 27.0% | 33.1% | 24.0% | 21.0% | 16.1% | 20.0% | 32.0% |
For the Sep 2026 quarter, Acutaas Chemicals reported sales of ₹437 Cr, up 42.7% year on year and net profit of ₹123 Cr, up 71.0% year on year. The operating margin was 40.0%.
Acutaas Chemicals' sales for the year to Mar 2026 were ₹1,340 Cr; over the last twelve months they were ₹1,593 Cr.
Net profit for the year to Mar 2026 was ₹356 Cr, and ₹438 Cr over the last twelve months. Earnings per share over the same trailing period were ₹53.58.
Acutaas Chemicals reported borrowings of ₹36.12 Cr at Mar 2026, against cash and equivalents of ₹225 Cr.
Cash from operations was ₹292 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹35.96 Cr.